Skip to Content

Pro Medicus Ltd PME

Morningstar Rating
A$109.38 +1.46 (1.35%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Not Much to Dislike About Pro Medicus' Business Model, but Shares Screen as Expensive

Pro Medicus’ strategy revolves around renewing existing contracts and winning new clients for its main product, Visage 7, while increasing its price point. The company won six out of six major public tenders it competed for in fiscal 2021, which often involved on-site pilot tests. While this likely highlights Visage 7’s current superior speed, scalability, and resilience, continued investment in research and development is imperative for the firm to remain at the forefront of innovation and consistently win contracts. Most of the firm’s expenses are allocated to over 40 software engineers with the main R&D center located in Berlin. The company also recently extended its R&D capability in New York in collaboration with NYU Langone Health in 2021. Its R&D efforts mostly revolve around software enhancements, program extensions, and research in artificial intelligence to assist in diagnoses.

Price vs Fair Value

PME is trading at a 213% premium.
Price
A$107.92
Fair Value
A$49.30
Uncertainty
High
1-Star Price
A$11.37
5-Star Price
A$23.80
Economic Moat
Ghkkjm
Capital Allocation
Fhlkxkpp

Bulls Say, Bears Say

Bulls

Pro Medicus is well positioned to benefit from industry tailwinds such as cloud adoption, larger datasets, and remote access.

Bears

Product differentiation is unlikely to be durable, with low barriers to entry and larger competitors already utilizing server-side rendering and cloud-native architecture.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PME is a good fit for your portfolio.

News

Trading Information

Previous Close Price
A$107.92
Day Range
A$106.98110.41
52-Week Range
A$58.60111.89
Bid/Ask
A$108.55 / A$109.90
Market Cap
A$11.42 Bil
Volume/Avg
206,003 / 349,012

Key Statistics

Price/Earnings (Normalized)
160.66
Price/Sales
78.92
Dividend Yield (Trailing)
0.32%
Dividend Yield (Forward)
0.33%
Total Yield
0.33%

Company Profile

Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are U.S. private academic hospitals. In fiscal 2022, Pro Medicus earned 79% of revenue in North America, 16% from Australia, and the remaining 6% in Europe.
Sector
Healthcare
Industry
Health Information Services
Stock Style Box
Large Growth
Total Number of Employees
75

Competitors

Valuation

Metric
PME
RMD
FPH
Price/Earnings (Normalized)
160.6628.5657.81
Price/Book Value
70.346.518.82
Price/Sales
78.926.679.07
Price/Cash Flow
157.0123.9939.48
Price/Earnings
PME
RMD
FPH

Financial Strength

Metric
PME
RMD
FPH
Quick Ratio
7.341.321.06
Current Ratio
7.493.042.54
Interest Coverage
22.6325.77
Quick Ratio
PME
RMD
FPH

Profitability

Metric
PME
RMD
FPH
Return on Assets (Normalized)
35.76%15.75%12.48%
Return on Equity (Normalized)
50.95%24.94%16.75%
Return on Invested Capital (Normalized)
48.23%19.33%15.46%
Return on Assets
PME
RMD
FPH
See how this stock stacks up to its competitors with Morningstar Investor

Health Information Services Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
GEHC
GE HealthCare Technologies Inc Common StockKzndyvj$39.4 Bil
VEEV
Veeva Systems Inc Class ATzgvlxrlxqCwdgp$32.4 Bil
SOLV
Solventum CorpMzktc$11.1 Bil
MTHRF
M3 IncMkhyns$8.2 Bil
MTHRY
M3 Inc ADRHrdcwpb$8.2 Bil
PMCUF
Pro Medicus LtdCfcwr$7.5 Bil
HQY
HealthEquity IncFqybczh$6.8 Bil
RCM
R1 RCM IncFsgy$5.0 Bil
DOCS
Doximity Inc Class ALkjjb$4.4 Bil
EVH
Evolent Health Inc Class APcqx$3.3 Bil

Sponsor Center